ILM1.F · Medios AG

-

Please sign in to comment on ILM1.F

1 Comment

Admin

3 years, 7 months ago

Medios AG is currently in a long term downtrend where the price is trading 0.4% below its 200 day moving average.

From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.9.

Medios AG's total revenue rose by 19.6% to $174M since the same quarter in the previous year.

Its net income has dropped by 0.4% to $2M since the same quarter in the previous year.

Finally, its free cash flow fell by 926.5% to $-46M since the same quarter in the previous year.

Based on the above factors, Medios AG gets an overall score of 2/5.

CurrencyCode	EUR
Exchange	F
Industry	Medical Distribution
Sector	Healthcare
ISIN	DE000A1MMCC8

PE Ratio	24.68
Market Cap	452M
Dividend Yield	0.0%
Target Price	None
Beta	1.24

ABOUT

Medios AG

Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment includes cytostatic infusion preparations, antibody therapies, virostatic and antibiotic medications, parenteral nutrition solutions, and investigational medicinal products. The company was founded in 2016 and is headquartered in Berlin, Germany.

ILM1.F · Medios AG

-

Medios AG

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Medios AG using a moving average strategy